Immune Thrombocytopenia (ITP) Market 2025: Opportunity Analysis and Forecasts
"The
Latest Research Report OpportunityAnalyzer: Immune Thrombocytopenia
(ITP) - Opportunity Analysis and Forecasts to 2025 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Immune Thrombocytopenia Market
Immune Thrombocytopenia (ITP) is
an auto-immune-related bleeding disorder characterized by a low
platelet count. Patients with severe ITP often experience fatigue,
bruising, and reduced quality of life. Although most ITP cases are
not fatal, approximately 3% of chronic refractory ITP patients die of
complications, such as intracranial hemorrhage and infection. Most of
the ITP treatments available are off-label drugs. In 2008, a class of
new drug, the thrombopoietin receptor agonists (TRAs), was approved
and revolutionized the treatment of ITP.
GlobalData estimates the 2015
sales for ITP at approximately $928m across the 7MM covered in this
report. The market is expected to grow modestly to $985m in 2025, at
a CAGR of 0.6%. This growth will be mainly driven by the increasing
uptake of TRAs, Amgen/Kirins Nplate/Romiplate (romiplostim) and
Novartis Promacta/Revolade (eltrombopag). However, GlobalData
expects, starting in 2022, Nplate and Promacta will face patent
expiry and subsequent biosimilar/generic erosion; this represents the
strongest barrier of ITP market growth.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1135703
The ITP pipeline activity is weak,
with only one active late-stage pipeline agent, Rigel Pharmaceuticals
fostamatinib; however, GlobalData expects this drug to struggle for
uptake because of the modest efficacy shown in its pivotal trials.
Overall, the treatment landscape of ITP is not anticipated to
substantially change throughout the forecast period of 2015-2025.
Key Questions Answered
- What are the key drivers behind
the increasing uptake and market penetration of the TRA-class
molecules, since their approval in 2008, and what is the trend of TRA
use in the forecast period?
- When will the key patent of
Nplate and Promacta expire, and how will it affect drug sales and the
overall ITP market in the 7MM?
- What are the struggles for
pipeline drug development in the ITP market? Why does GlobalData
expect the pipeline drugs to introduce minimal impacts on the
marketspace during the forecast period?
Scope
- Overview of ITP, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
disease management.
- Annualized ITP therapeutics
market revenue, cost of therapy per patient, and treatment usage
patterns in three patient segments (including pediatric, adult
primary, and adult secondary), forecast from 2015 to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the ITP
therapeutics market
- Pipeline analysis: comprehensive
data assessing emerging trends and mechanisms of action under
development for ITP therapy. The most promising candidate in Phase
III development is profiled.
- Analysis of the current and
future market competition in the global ITP therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global ITP
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global ITP therapeutics
market in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1135703
Table of Contents
1 Table of Contents 8
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology
20
3.1.1 Etiology 20
3.1.2 Pathophysiology 22
3.2 Phases and Severity of ITP 24
3.3 Symptoms 25
3.4 Prognosis 26
3.5 Quality of Life 27
4 Epidemiology 29
4.1 Disease Background 29
4.2 Risk Factors and Comorbidities
29
4.3 Global Trends 31
4.3.1 US 33
4.3.2 5EU 34
4.3.3 Japan 35
4.4 Forecast Methodology 35
4.4.1 Sources Used Tables 36
4.4.2 Forecast Assumptions and
Methods 39
4.4.3 Sources Not Used 47
4.5 Epidemiological Forecast for
ITP (2015-2025) 48
4.5.1 Diagnosed Prevalent Cases of
ITP 48
4.5.2 Age-Specific Diagnosed
Prevalent Cases of ITP 52
4.5.3 Sex-Specific Diagnosed
Prevalent Cases of ITP 56
4.5.4 Age-Standardized Diagnosed
Prevalence of ITP 60
4.5.5 Diagnosed Incident Cases of
ITP 63
4.5.6 Age-Specific Diagnosed
Incident Cases of ITP 67
4.5.7 Sex-Specific Diagnosed
Incident Cases of ITP 71
4.5.8 Age-Standardized Diagnosed
Incidence of ITP 75
4.6 Discussion 77
4.6.1 Epidemiological Forecast
Insight 77
4.6.2 Limitations of the Analysis
79
4.6.3 Strengths of the Analysis 80
5 Current Treatment Options 81
5.1 Overview 81
5.2 Diagnosis and Treatment 81
5.2.1 Diagnosis 82
5.2.2 Treatment Guidelines and
Leading Prescribed Drugs 85
5.3 Clinical Practice 86
5.3.1 Decision on the Initiation
of Treatment 86
5.3.2 First-Line Treatment 89
5.3.3 Second-Line Therapy 96
5.4 Product Profiles -
Thrombopoietin Receptor Agonists 108
5.4.1 Nplate (Romiplostim) 108
5.4.2 Promacta/Revolade
(Eltrombopag) 123
6 Unmet Needs Assessment and
Opportunity Analysis 139
6.1 Overview 139
6.2 Safer and More Efficacious
First-Line Therapy 139
6.2.1 Unmet Need 139
6.2.2 Gap Analysis 140
6.2.3 Opportunity 141
6.3 High Treatment Cost of
Thrombopoietin Receptor Agonists 141
6.3.1 Unmet Need 141
6.3.2 Gap Analysis 142
6.3.3 Opportunity 143
6.4 Second-Line Therapeutic
Options that Offer Long-Term Remission 143
6.4.1 Unmet Need 143
6.4.2 Gap Analysis 144
6.4.3 Opportunity 145
6.5 New Treatment for Multiple
Drug Refractory Patients 146
6.5.1 Unmet Need 146
6.5.2 Gap Analysis 146
6.5.3 Opportunity 147
6.6 Difficulties in Clinical Trial
Patient Recruitment 147
6.6.1 Unmet Need 147
6.6.2 Gap Analysis 148
6.6.3 Opportunity 149
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment